Healthcare Services

Non-Cystic Fibrosis Bronchiectasis Market 2026–2030: Forecast, Innovation, and Competitive Trends

February 27, 2026April 15, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the non-cystic fibrosis bronchiectasis market from 2026–2035 with trusted insights from The Business Research Company

How much is the Non-Cystic Fibrosis Bronchiectasis Market valued at in 2026, and what valuation is forecast for 2030?

The non-cystic fibrosis bronchiectasis market has experienced substantial expansion in recent years. Its valuation is anticipated to rise from $3.7 billion in 2025 to $3.93 billion in 2026, progressing at a compound annual growth rate (CAGR) of 6.4%. This historic growth is largely due to factors including recurrent respiratory infections, restricted understanding of non-CF bronchiectasis, a dependence on established diagnostic techniques, insufficient hospital infrastructure, and the limited embrace of advanced imaging technologies.

The non-cystic fibrosis bronchiectasis market is projected to experience substantial expansion in the coming years. By 2030, its value is forecast to reach $4.92 billion, growing at a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing incidence of chronic respiratory conditions, the wider adoption of AI and precision medicine, the expansion of home healthcare and telemedicine services, progress in minimally invasive treatment options, and the enhancement of healthcare infrastructure within developing economies. Key trends anticipated during this period involve the increasing embrace of personalized treatment strategies, greater integration of remote patient monitoring and telehealth solutions, a rise in the application of AI-powered diagnostic instruments, broader deployment of connected health devices and smart lung monitoring systems, and the progressive integration of data-driven tools for clinical decision support.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17209&type=smp

What Drivers Are Influencing The Growth Of The Non-Cystic Fibrosis Bronchiectasis Market?

An increasing incidence of respiratory illnesses is projected to fuel expansion in the non-cystic fibrosis bronchiectasis market moving ahead. These diseases encompass various ailments that target the lungs and respiratory tract, thereby impairing respiration and general respiratory performance. The growing occurrence of respiratory conditions is chiefly propelled by escalating environmental contamination, involving both external pollutants and internal irritants like tobacco smoke. This surge in respiratory infections offers prospects for enhancing the comprehension, identification, and treatment of non-cystic fibrosis bronchiectasis via focused initiatives and public health campaigns. As an illustration, in June 2023, data from a report by the Office for Health Improvement and Disparities, a UK government agency, indicated that a total of 4,622 notifications of scarlet fever Group A Streptococcus bacteria were recorded from week 37 to week 46 in the 2022-2023 season in England, with 851 notifications specifically in week 46 alone. This figure represents a considerable increase when contrasted with an average of 1,294 notifications (ranging from 258 to 2,008) for the identical period (weeks 37 to week 46) over the preceding five years. Consequently, the increasing occurrence of respiratory ailments is set to boost the expansion of the non-cystic fibrosis bronchiectasis market.

What Segments Are Included Within The Non-Cystic Fibrosis Bronchiectasis Market?

The non-cystic fibrosis bronchiectasis market covered in this report is segmented –

1) By Diagnosis: Computed Tomography (CT) Scan, Bronchoscopy, Chest X Ray, Lung Function, Sputum Culture Test, Blood Tests, Other Diagnosis Types

2) By Treatment: Surgery, Physiotherapy, Vaccination, Airway Pharmacotherapy, Antibiotics, Other Treatments

3) By End Use: Hospitals And Clinics, Ambulatory Care Centers, Other End Uses

Subsegments:

1) By Computed Tomography (CT) Scan: High-Resolution CT (HRCT), Standard CT

2) By Bronchoscopy: Flexible Bronchoscopy, Rigid Bronchoscopy

3) By Chest X-Ray: Standard Chest X-Ray, Digital Chest X-Ray

4) By Lung Function: Spirometry, Peak Flow Measurement

5) By Sputum Culture Test: Bacterial Culture, Fungal Culture, Viral Culture

6) By Blood Tests: Complete Blood Count (CBC), C-Reactive Protein (CRP), Immunoglobulin Levels

7) By Other Diagnosis Types: Sweat Test, Genetic Testing, Exhaled Nitric Oxide Test

Which Innovation Trends Are Advancing Developments Within The Non-Cystic Fibrosis Bronchiectasis Market?

Key companies operating in the non-cystic fibrosis bronchiectasis (NCFB) market are concentrating on developing advanced solutions, such as novel pharmacologic interventions that regulate neutrophil elastase, to enhance protease–antiprotease balance, alleviate chronic tissue damage, and support ongoing control of airway remodeling. This type of novel neutrophil elastase–regulating pharmacologic intervention for chronic airway inflammation represents a targeted therapeutic approach designed to modify excessive neutrophil elastase activity, which is a fundamental contributor to airway injury and persistent inflammation in NCFB. As an illustration, in November 2025, Insmed, a US-based biopharmaceutical company, secured European Commission approval for BRINSUPRI (brensocatib), a groundbreaking, once-daily oral DPP1 inhibitor. The 25 mg formulation, demonstrated in the Phase 3 ASPEN trial, led to a 19.4% reduction in annual exacerbation rate compared to placebo, extended the duration to the first exacerbation, and showed a greater proportion of patients staying exacerbation-free. Moreover, it significantly mitigated the decline in lung function (FEV1) at week 52 and presented a favorable safety profile, with common adverse effects reported including headache, hyperkeratosis, dermatitis, rash, upper respiratory tract infections, and dry skin.

Who Are The Top-Performing Companies In The Non-Cystic Fibrosis Bronchiectasis Market In Recent Years?

Major companies operating in the non-cystic fibrosis bronchiectasis market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Dr Reddys Laboratories Ltd., Chiesi Farmaceutici SpA, Lupin Limited, Zambon Company SpA, Sunovion Pharmaceuticals Inc., Insmed Incorporated, Armata Pharmaceuticals Inc., Renovion Inc., SolAeroMed Inc., CSL Behring, Haisco Pharmaceutical Group Co Ltd., NovaBiotics Ltd., Synspira Therapeutics, Parion Sciences, Regeneron Pharmaceuticals Inc., Gilead Sciences Inc., Infex Therapeutics

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/non-cystic-fibrosis-bronchiectasis-global-market-report

How Does The Non-Cystic Fibrosis Bronchiectasis Market Perform Across Major Global Regions?

North America was the largest region in the non-cystic fibrosis bronchiectasis market in 2025. The regions covered in the non-cystic fibrosis bronchiectasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Non-Cystic Fibrosis Bronchiectasis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17209&type=smp

Browse Through More Reports Similar to the Global Non-Cystic Fibrosis Bronchiectasis Market 2026, By The Business Research Company

Bronchoscope Market Report 2026

https://www.thebusinessresearchcompany.com/report/bronchoscope-global-market-report

Idiopathic Pulmonary Fibrosis Market Report 2026

https://www.thebusinessresearchcompany.com/report/idiopathic-pulmonary-fibrosis-global-market-report

Cystic Fibrosis Cf Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795